Ikenaga, H.; Kozuka, R.; Inoue, K.; Matsubara, T.; Odagiri, N.; Yoshida, K.; Kotani, K.; Kawamura, E.; Hagihara, A.; Fujii, H.;
et al. 12-Hydroxyheptadecatrienoic Acid Predicts Hepatocellular Carcinoma Development During Nucleos(t)ide Analogue Therapy. Cancers 2026, 18, 542.
https://doi.org/10.3390/cancers18040542
AMA Style
Ikenaga H, Kozuka R, Inoue K, Matsubara T, Odagiri N, Yoshida K, Kotani K, Kawamura E, Hagihara A, Fujii H,
et al. 12-Hydroxyheptadecatrienoic Acid Predicts Hepatocellular Carcinoma Development During Nucleos(t)ide Analogue Therapy. Cancers. 2026; 18(4):542.
https://doi.org/10.3390/cancers18040542
Chicago/Turabian Style
Ikenaga, Hiroko, Ritsuzo Kozuka, Kirara Inoue, Tsutomu Matsubara, Naoshi Odagiri, Kanako Yoshida, Kohei Kotani, Etsushi Kawamura, Atsushi Hagihara, Hideki Fujii,
and et al. 2026. "12-Hydroxyheptadecatrienoic Acid Predicts Hepatocellular Carcinoma Development During Nucleos(t)ide Analogue Therapy" Cancers 18, no. 4: 542.
https://doi.org/10.3390/cancers18040542
APA Style
Ikenaga, H., Kozuka, R., Inoue, K., Matsubara, T., Odagiri, N., Yoshida, K., Kotani, K., Kawamura, E., Hagihara, A., Fujii, H., Enomoto, M., & Uchida-Kobayashi, S.
(2026). 12-Hydroxyheptadecatrienoic Acid Predicts Hepatocellular Carcinoma Development During Nucleos(t)ide Analogue Therapy. Cancers, 18(4), 542.
https://doi.org/10.3390/cancers18040542
